Summary auto-generated
This study investigates how the polyene antibiotic MS-8209 prevents scrapie infection in mice. Scrapie is a transmissible spongiform encephalopathy characterized by accumulation of abnormal prion protein in the nervous system. The researchers used immunodeficient SCID mice, which lack functional lymphocytes but can still develop scrapie when infected peripherally, allowing direct study of neuroinvasion bypassing the lymphoreticular system. SCID mice treated with MS-8209 showed a threefold reduction in disease transmission compared to controls, though surviving animals had similar incubation periods. In immunologically reconstituted SCID mice, MS-8209 delayed but did not prevent disease. These findings indicate MS-8209 blocks the early stages of neuroinvasion—specifically the uptake of scrapie agent by peripheral nerve endings. The drug's mechanism likely involves disruption of nerve terminal membranes or enhancement of macrophage clearance of the infectious agent. The results identify the neuroimmune interface as a vulnerable point in scrapie pathogenesis and suggest it is a promising target for therapeutic intervention following peripheral TSE contamination.
Key findings
- MS-8209 treatment reduced scrapie transmission in SCID mice by 70% (from 44% to 14% infection rate) without delaying clinical onset in infected animals, indicating it blocks early neuroinvasion rather than late-stage disease progression
- The drug was effective in immunodeficient SCID mice lacking functional lymphoid tissue, demonstrating its action is independent of lymphoreticular system function and targets peripheral nerve uptake of the scrapie agent
- MS-8209 only delayed disease in immunologically reconstituted mice with functional immune systems, confirming the drug prevents neuroinvasion by blocking agent propagation to peripheral nerves before the lymphoreticular system can establish chronic replication
- The neuroimmune interface—the junction between the lymphoreticular system and peripheral nervous system—represents a vulnerable point in scrapie pathogenesis susceptible to drug intervention
This summary was generated automatically from the article PDF and is not part of the original publication. Refer to the PDF for the authoritative text.
Abstract
V Beringue, CI Lasmezas, KT Adjou, R Demaimay, F Lamoury, JP Deslys, M Seman and D Dormont
CEA, Service de Neurovirologie, DSV/DRM, CRSSA, 60--68 av. Division Leclerc, BP 6, 92265 Fontenay aux Roses Cedex, France
The polyene antibiotic MS-8209 is currently one of the most effective drugs in the treatment of experimental scrapie. However, its mechanism of action and its site of intervention in the pathogenetical process of scrapie infection are largely unknown. It has been shown previously that the infection of immunodeficient SCID mice by the peripheral route provides a reliable model for direct scrapie neuroinvasion, bypassing the lymphoreticular system. Indeed, a proportion of SCID mice develop scrapie after a similar time to immunocompetent mice, despite their severe immune impairment. This model is now used to clarify the targets of MS-8209. In SCID mice, MS-8209 treatment protected against infection but did not prolong survival time. In SCID mice immunologically reconstituted prior to inoculation, the drug delayed the disease without an effect on the attack rate. These findings strongly suggest that MS-8209 acts by hampering the first step of the neuroinvasion process, i.e. the uptake of the infectious agent by peripheral nerve endings. The mechanism leading to the inhibition of agent propagation to nervous cells is discussed with regard to the properties of polyene antibiotics.